Skip to main
ARTV

ARTV Stock Forecast & Price Target

ARTV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artiva Biotherapeutics is a biopharmaceutical company with a strong pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies and solid tumors. The upcoming Phase IIa readout of AlloNK in patients with refractory rheumatoid arthritis (RA) is highly anticipated, given the potential for deep B-cell aplasia and durable response rates. We believe that AlloNK has the potential to perform just as well or better than current treatments in this indication, potentially securing a competitive position in the rapidly emerging cell therapy market.

Bears say

Artiva Biotherapeutics is currently a small biopharmaceutical company with a limited pipeline and no approved drugs. Their lead candidate, AlloNK, is facing safety concerns and has not demonstrated exceptional efficacy in clinical trials so far. In addition, the regulatory landscape for cell therapies is still evolving and may pose challenges for approval. As a result, the company's competitive position in the market is weak, and it may struggle to generate significant revenue in the near future.

ARTV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast

Analysts have given ARTV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ARTV has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artiva Biotherapeutics Inc (ARTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.